<code id='DA70DD58D3'></code><style id='DA70DD58D3'></style>
      • <acronym id='DA70DD58D3'></acronym>
      <center id='DA70DD58D3'><center id='DA70DD58D3'><tfoot id='DA70DD58D3'></tfoot></center><abbr id='DA70DD58D3'><dir id='DA70DD58D3'><tfoot id='DA70DD58D3'></tfoot><noframes id='DA70DD58D3'>
      • <optgroup id='DA70DD58D3'><strike id='DA70DD58D3'><sup id='DA70DD58D3'></sup></strike><code id='DA70DD58D3'></code></optgroup>
        5. <b id='DA70DD58D3'><label id='DA70DD58D3'><select id='DA70DD58D3'><dt id='DA70DD58D3'><span id='DA70DD58D3'></span></dt></select></label></b><u id='DA70DD58D3'></u>
          <i id='DA70DD58D3'><strike id='DA70DD58D3'><tt id='DA70DD58D3'><pre id='DA70DD58D3'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / comprehensive / entertainment      
           
     
           
      
          entertainment 
           
      
           
      
           
       2025-09-29 22:24:57 
   
      
           
      
           
                        
          entertainment  
          
                                   
                 
                                      author：knowledge   
                                        
                                      
                                      Page View：56685
                                  
                                    
          
                                   
          Bristol Myers Squibb sign
          Courtesy Bristol Myers Squibb
          Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.
          RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.
          advertisement
          Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Masked assailants attack a journalist and a lawyer in Russia's Chechnya province
                                
                            
          Next article：  
                                      
                                          Duchenne breakthrough therapy leaves behind pioneering families
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles